Company / PP&E (Net)
Xeris Biopharma Holdings, Inc. PP&E (Net) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$4.9M
FY2025
5-year range
$4.9M / $6.6M
FY2021-FY2025
Trend
-11.1%
vs FY2024
Sector context
#113 of 193
Health Care
What the data says
At $5M, Xeris Biopharma Holdings, Inc.'s pp&e (net) ranks #113 of 193 in the Health Care sector. Declined from $6M to $5M over the past 2 years.
Based on SEC 10-K filings.
$5M in FY2025 with a 5-year CAGR of -5.9%.
Declined from $6M to $5M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -3.6%
- 5-Year CAGR
- -5.9%
- 10-Year CAGR
- -
Sector benchmark
#113 of 193 in Health CareTop 59% of 193This company $4.9M Sector average $777.6M
▼
-99.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -5.9%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 11.1% year-over-year.
- Ranks #113 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.9M | -11.1% |
| FY2024 | $5.6M | -6.8% |
| FY2023 | $6.0M | +8.2% |
| FY2022 | $5.5M | -16.8% |
| FY2021 | $6.6M | -1.2% |
| FY2020 | $6.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026